Equity Overview
Price & Market Data
Price: $6.98
Daily Change: -$0.04 / 0.57%
Range: $6.58 - $7.03
Market Cap: $478,982,944
Volume: 495,514
Performance Metrics
1 Week: -14.77%
1 Month: 14.43%
3 Months: 17.51%
6 Months: -18.65%
1 Year: -50.46%
YTD: -4.64%
Company Details
Employees: 69
Sector: Health technology
Industry: Pharmaceuticals: other
Country: France
Details
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.